general condition improved. Her Echocardiography showed normal LV wall motion, right ventricular and LV pressures were almost same, but the peak velocity of pulmonary flow was 3.9 m/s, and the estimated pulmonary arterial pressure was 30 mmHg. Therefore, administration of buprenorphine and midazolam was ceased on day 34 of mechanical ventilation after a 4-day staged withdrawal. On the evening of the 34th day, she began perspire heavily and developed tachycardia (170 beats/min). The next morning, hypotension (63/48 mmHg) and body weight loss (from 7,100 to 6,935 g) were obvious (Fig 1) . A 12-lead electrocardiogram (ECG) revealed ST segment elevation and negative Twaves in leads 1, II, and V4-6 ( Fig 2) . Echocardiography showed akinesis with dilatation and systolic ballooning of the LV apical segment (Fig 3) . Blood examination showed slightly elevated values for transaminases (aspartate aminotransferase: 59 IU/L, alanine aminotransferase: 45 IU/L) and normal values of creatine kinase (51 IU/L), troponin T (low), and myoglobin (<30 ng/ml). After buprenorphine and midazolam administration was resumed, together with dopamine and dobutamine, the tachycardia and heavy perspiration disappeared. Lidocaine administration was also started after direct current defibrillation for the ventricular tachycardia. Two days later, there was recovery of LV wall motion on echocardiograpy and the ECG showed negative T-waves in V4-6 and prolonged QT intervals (Fig 2) . The ECG findings improved within 2 weeks. After this episode, administration of buprenorphine and midazolam were withdrawn slowly, and finally she was weaned from the mechanical ventilation support.
Discussion
Takotsubo cardiomyopathy is a cardiac syndrome comprising transient LV dysfunction with chest symptoms and ECG changes that mimic those of acute myocardial infarction. 2, 9 The clinical features of takotsubo cardiomyopathy are as follows: 2, [9] [10] [11] [12] (1) transient LV apical ballooning on echocardiography or ventriculography that normalizes rapidly within a few weeks; (2) ST elevation on ECG at onset and then T-wave inversion in many leads, which increases a few days after the onset, and the QT-interval is prolonged; (3) mild peaks of creatine kinase, troponin etc. (4) rapid improvement within a few weeks in most cases, and recovery is satisfactory.
The present case had typical clinical features and the diagnosis was established retrospectively after her recovery from the acute symptoms. However, it is unknown whether takotsubo cardiomyopathy occurs in young children, because the mechanisim of this cardiac abnormality has not yet been completely clarified. Therefore, the appropriate diagnosis of the present case is suspected takotsubo cardiomyopathy.
The incidence of takotsubo cardiomyopathy is approximately one in 150-200 adult cases of acute coronary syndrome. [3] [4] [5] [6] [7] [8] 13 The majority of patients are older: the mean age is 66 years in men and 69 years in women. 13 Cases of takotsubo cariomyopathy are rarely reported in younger adults, therefore pediatric cardiologist would not be aware of it and cases in children may have been overlooked.
Various psychological and physical conditions are reported as possible triggering factors, including sudden accidents, aggravation of systemic disease, or surgery. 2, 9, 14 The present patient developed heavy perspiration and tachycardia after withdrawal of buprenorphine and midazolam. Buprenorphine is an opioid partial agonist that is used for the treatment of acute and chronic pain. Mixed agonistantagonists analgesics are commercially available for anal- gesia, but prolonged use of buprenorphine can result in physical dependence. 15 Symptoms of withdrawal include central nervous irritability, gastrointestinal dysfunction, and autonomic dysfunction, 16 such as the perspiration and tachycardia observed in our patient. A relationship between enhanced sympathetic activity and takotsubo cardiomyopathy has been postulated. 2 Therefore, stress and/or enhanced sympathetic activity caused by the withdrawal of buprenorphine are the most likely factors triggering takotsubo cardiomyopathy in the present case. More careful withdrawal of buprenorphine and midazolam may be necessary to prevent the occurrence of takotsubo cardiomyopathy in young children.
The specific therapy for takotsubo cardiomyopathy has not been established; however, management of pump failure and arrhythmia is important, 2 as is eliminating triggering factor(s). The present patient improved after re-starting buprenorphine and midazolam with administration of catecholamines and lidocaine.
In summary, a young child developed suspected takotsubo cardiomyopathy in addition to symptoms of withdrawal from buprenorphine. Awareness of the occurrence of a phenomenon similar to takotsubo cardiomyopathy, even in young children, may be important for pediatric cardiologists.
